OncRef

Clinical Trial: NCT03511664

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Endocyte
Information Provided By:Endocyte
Last Update Posted:2025-01-13

Study Overview

Brief Summary

The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

Official Title

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Conditions

Prostate Cancer

Intervention / Treatment

  • Drug: 177Lu-PSMA-617
  • Other: Best supportive/best standard of care

Other Study ID Numbers

  • PSMA-617-01
  • 2018-000459-41
  • CAAA617A12301
  • 2018

Start Date (Actual)

2018-05-29

Primary Completion Date (Actual)

2021-01-27

Study Completion Date (Actual)

2023-12-14

Enrollment (Actual)

861

Study Type

Interventional

Phase

Phase 3